
Tags Archive Navigation
icon
-
Media ReleaseNovartis unveils results from global patient and physician survey disrupting the notion that CML is a solved disease
-
Media ReleaseNovartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
-
Media ReleaseNovartis receives European approval for Cosentyx® as first and only IL-17A inhibitor for hidradenitis suppurativa
-
StoryThe future of medicine is here
-
Media ReleaseNovartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting
-
Media ReleaseNovartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa
-
Media ReleaseNovartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
-
Media ReleaseNovartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients
-
Media ReleaseNovartis erzielt kräftige Umsatzsteigerungen, eine robuste Margenerhöhung und wichtige Innovationsmeilensteine. Erhöhung der Jahresprognose
-
Media ReleaseNovartis réalise une croissance forte de son chiffre d’affaires, une expansion robuste de sa marge, des étapes majeures de l’innovation et rehausse ses prévisions pour l’exercice 2023
-
Media ReleaseNovartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance
-
Media ReleaseNovartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis